ScoreWhy is Anhui Anke Biotechnology (Group) Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 6.52% and Operating profit at 11.86% over the last 5 years
2
Flat results in Mar 26
- ROCE(HY) Lowest at 15.72%
- NET SALES(Q) Lowest at CNY 541.72 MM
- OPERATING PROFIT(Q) Lowest at CNY 188.32 MM
3
With ROE of 14.76%, it has a fair valuation with a 1.94 Price to Book Value
- Over the past year, while the stock has generated a return of -8.42%, its profits have fallen by -0%
- At the current price, the company has a high dividend yield of 3.1
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -8.42% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Anhui Anke Biotechnology (Group) Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Anhui Anke Biotechnology (Group) Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Anhui Anke Biotechnology (Group) Co., Ltd.
-17.6%
-0.27
39.33%
China Shanghai Composite
3.0%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.52%
EBIT Growth (5y)
11.86%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.64
Tax Ratio
9.53%
Dividend Payout Ratio
56.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
31.52%
ROE (avg)
18.43%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.64
EV to EBIT
14.73
EV to EBITDA
13.05
EV to Capital Employed
3.50
EV to Sales
4.26
PEG Ratio
NA
Dividend Yield
2.31%
ROCE (Latest)
23.72%
ROE (Latest)
14.76%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0.8% (YoY
CASH AND EQV(HY)
Highest at CNY 3,089.74 MM
-8What is not working for the Company
NET SALES(Q)
At CNY 556.18 MM has Fallen at -13.08%
INTEREST COVERAGE RATIO(Q)
Lowest at 32,991.88
Here's what is working for Anhui Anke Biotechnology (Group) Co., Ltd.
Cash and Eqv
Highest at CNY 3,089.74 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by 0.8% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Anhui Anke Biotechnology (Group) Co., Ltd.
Net Sales
At CNY 556.18 MM has Fallen at -13.08%
over average net sales of the previous four periods of CNY 639.87 MMMOJO Watch
Near term sales trend is very negative
Net Sales (CNY MM)
Interest Coverage Ratio
Lowest at 32,991.88
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Footer loading
